5月10日-17日，全球共达成18起资产授权和合作交易。中国医药市场共达成4起交易，包括3起出海交易和1起国内交易。最值得关注的交易是恒瑞医药将旗下GLP-1产品组合授权美国Hercules CM Newco, Inc.，首付款1亿美元，总金额60.35亿美元，为2024年迄今为止总金额最大、首付款第二大的资产出海交易。
全球范围内，共签署了14项资产授权和合作协议。其中金额最大的一项是Novavax与Sanofi就NVX-CoV2373和Matrix-M™ 佐剂达成的首付5亿美元、总额12亿美元的授权交易。
From May 10 to 17, a total of 18 licensing and cooperation deals were sealed globally. In the China Biotech Industry, there were 3 out-licensing and 1 in-licensing deals signed. Hengrui Pharmaceuticals and Hercules CM Newco signed an out-licensing deal amounting to $6,035 million.
Globally, 14 cooperation and licensing deals were signed. The deal between Novavax and Sanofi for NVX-CoV2373 and the Matrix-M™ adjuvant topped this week, amounting to a total of $1,200 million with an upfront payment of $500 million.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit www.yafocapital.com
Event Name: ACCESS CHINA Partnering Forum @BIO
Date & Time: June 3-20, 2024
Venue: San Diego & Online
Content: Keynote Speeches, Panel Discussion, Virtual Roadshows, Dinner Reception, 1X1 meetings
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs.
